1
|
Toraih EA, Hussein MH, Al Ageeli E, Ellaban M, Kattan SW, Moroz K, Fawzy MS, Kandil E. Matrix Metalloproteinase 9/microRNA-145 Ratio: Bridging Genomic and Immunological Variabilities in Thyroid Cancer. Biomedicines 2023; 11:2953. [PMID: 38001954 PMCID: PMC10669161 DOI: 10.3390/biomedicines11112953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 10/15/2023] [Accepted: 10/23/2023] [Indexed: 11/26/2023] Open
Abstract
Matrix metalloproteinase 9 (MMP9) and microRNA-145 (miR-145) have emerged as essential biomarkers in thyroid cancer progression and metastasis. However, their combined evaluation and clinical utility as a unified prognostic marker across diverse thyroid cancer subgroups remain unexplored. We investigated the diagnostic and prognostic value of the MMP9/miR-145 ratio in thyroid cancer, hypothesizing it may overcome inter-patient heterogeneity and serve as a versatile biomarker regardless of genetic mutations or autoimmune status. MMP9 and miR-145 expressions were analyzed in 175 paired papillary thyroid cancer (PTC) and normal tissues. Plasma levels were assessed perioperatively and longitudinally over 12-18 months in 86 matched PTC patients. The associations with clinicopathological parameters and patient outcomes were evaluated. MMP9 was upregulated, and miR-145 downregulated in cancer tissues, with a median MMP9/miR-145 ratio 17.6-fold higher versus controls. The tissue ratio accurately diagnosed thyroid malignancy regardless of BRAF mutation or Hashimoto's thyroiditis status, overcoming genetic and autoimmune heterogeneity. A high preoperative circulating ratio predicted aggressive disease features, including lymph node metastasis, extrathyroidal extension, progression/relapse, and recurrence. Although the preoperative plasma ratio was elevated in patients with unfavorable outcomes, it had limited utility for post-surgical monitoring. In conclusion, the MMP9/miR-145 ratio is a promising biomarker in PTC that bridges genetic and immunological variabilities, enhancing preoperative diagnosis and prognostication across diverse patient subgroups. It accurately stratifies heterogenous cases by aggressiveness. The longitudinal trends indicate decreasing applicability for post-thyroidectomy surveillance. Further large-scale validation and protocol standardization can facilitate clinical translation of the MMP9/miR-145 ratio to guide personalized thyroid cancer management.
Collapse
Affiliation(s)
- Eman A. Toraih
- Division of Endocrine and Oncologic Surgery, Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA; (M.H.H.); (E.K.)
- Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt
| | - Mohamed H. Hussein
- Division of Endocrine and Oncologic Surgery, Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA; (M.H.H.); (E.K.)
| | - Essam Al Ageeli
- Department of Clinical Biochemistry (Medical Genetics), Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia;
| | - Mohamad Ellaban
- Faculty of Medicine, Port Said University, Port Said 42526, Egypt;
| | - Shahd W. Kattan
- Department of Medical Laboratory, College of Applied Medical Sciences, Taibah University, Yanbu 46411, Saudi Arabia;
| | - Krzysztof Moroz
- Department of Pathology and Laboratory Medicine, School of Medicine, Tulane University, New Orleans, LA 70112, USA;
| | - Manal S. Fawzy
- Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt;
- Department of Biochemistry, Faculty of Medicine, Northern Border University, Arar 91431, Saudi Arabia
| | - Emad Kandil
- Division of Endocrine and Oncologic Surgery, Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA; (M.H.H.); (E.K.)
| |
Collapse
|
2
|
Pavlidis ET, Pavlidis TE. Role of prophylactic central neck lymph node dissection for papillary thyroid carcinoma in the era of de-escalation. World J Clin Oncol 2023; 14:247-258. [PMID: 37583949 PMCID: PMC10424091 DOI: 10.5306/wjco.v14.i7.247] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 06/14/2023] [Accepted: 07/03/2023] [Indexed: 07/19/2023] Open
Abstract
Thyroid cancer is the most common endocrine malignancy. While there has been no appreciable increase in the observed mortality of well-differentiated thyroid cancer, there has been an overall rise in its incidence worldwide over the last few decades. Patients with papillary thyroid carcinoma (PTC) and clinical evidence of central (cN1) and/or lateral lymph node metastases require total thyroidectomy plus central and/or lateral neck dissection as the initial surgical treatment. Nodal status in PTC patients plays a crucial role in the prognostic evaluation of the recurrence risk. The 2015 guidelines of the American Thyroid Association (ATA) have more accurately determined the indications for therapeutic central and lateral lymph node dissection. However, prophylactic central neck lymph node dissection (pCND) in negative lymph node (cN0) PTC patients is controversial, as the 2009 ATA guidelines recommended that CND "should be considered" routinely in patients who underwent total thyroidectomy for PTC. Although the current guidelines show clear indications for therapeutic CND, the role of pCND in cN0 patients with PTC is still debated. In small solitary papillary carcinoma (T1, T2), pCND is not recommended unless there are high-risk prediction factors for recurrence and diffuse nodal spread (extrathyroid extension, mutation in the BRAF gene). pCND can be considered in cN0 disease with advanced primary tumors (T3 or T4) or clinical lateral neck disease (cN1b) or for staging and treatment planning purposes. The role of the preoperative evaluation is fund-amental to minimizing the possible detrimental effect of overtreatment of the types of patients who are associated with low disease-related morbidity and mortality. On the other hand, it determines the choice of appropriate treatment and determines if close monitoring of patients at a higher risk is needed. Thus, pCND is currently recommended for T3 and T4 tumors but not for T1 and T2 tumors without high-risk prediction factors of recurrence.
Collapse
Affiliation(s)
- Efstathios T Pavlidis
- 2nd Propedeutic Department of Surgery, Hippocration Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece
| | - Theodoros E Pavlidis
- 2nd Propedeutic Department of Surgery, Hippocration Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece
| |
Collapse
|
3
|
Wei W, Wu Y, Chen DD, Song Y, Xu G, Shi Q, Dong XP. Proteomics profiling for the global and acetylated proteins of papillary thyroid cancers. Proteome Sci 2023; 21:6. [PMID: 37101287 PMCID: PMC10131382 DOI: 10.1186/s12953-023-00207-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Accepted: 04/16/2023] [Indexed: 04/28/2023] Open
Abstract
BACKGROUND Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy cancer among the malignancies of thyroid. Despite of wide usages of proteomics in PTC, the profile of acetylated proteins in PTC remains unsettled, which is helpful for understanding the carcinogenesis mechanism and identifying useful biomarkers for PTC. METHODS The surgically removed specimens of cancer tissues (Ca-T) and adjacent normal tissues (Ca-N) from 10 female patients pathological diagnosed as PTC (TNM stage III) were enrolled in the study. After preparing the pooled extracts of the whole proteins and the acetylated proteins from 10 cases, TMT labeling and LC/MS/MS methods were applied to the assays of global proteomics and acetylated proteomics separately. Bioinformatics analysis, including KEGG, gene ontology (GO) and hierarchical clustering were performed. Some differentially expressed proteins (DEPs) and differentially expressed acetylated proteins (DEAPs) were validated by individual Western blots. RESULTS Controlled with the normal tissues adjacent to the lesions, 147 out of 1923 identified proteins in tumor tissues were considered as DEPs in global proteomics, including 78 up-regulated and 69 down-regulated ones, while 57 out of 311 identified acetylated proteins in tumor tissues were DEAPs in acetylated proteomics, including 32 up-regulated and 25 down-regulated, respectively. The top 3 up- and down-regulated DEPs were fibronectin 1, KRT1B protein and chitinase-3-like protein 1, as well as keratin, type I cytoskeletal 16, A-gamma globin Osilo variant and Huntingtin interacting protein-1. The top 3 up- and down-regulated DEAPs were ribosomal protein L18a-like protein, alpha-1-acid glycoprotein 2 and eukaryotic peptide chain release factor GTP-binding subunit ERF3A, as well as trefoil factor 3, thyroglobulin and histone H2B. Functional GO annotation and KEGG pathway analysis based on the DEPs and DEAPs showed completely different changing pictures. Contrary to the top 10 up- and -down regulated DEPs, most of which were addressed in PTC and other types of carcinomas, changes of the majority DEAPs were not mentioned in the literatures. CONCLUSIONS Taken the profiling of the global and acetylated proteomics together will provide more broad view of protein alterations on the carcinogenesis and new direction for selecting biomarker for diagnosis of PTC.
Collapse
Affiliation(s)
- Wei Wei
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Head and Neck Surgery Department, Peking University Cancer Hospital & Institute, Beijing, 100142, China
| | - Yuezhang Wu
- State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases (Zhejiang University), National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Chang-Bai Rd 155, Beijing, 102206, China
| | - Dong-Dong Chen
- State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases (Zhejiang University), National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Chang-Bai Rd 155, Beijing, 102206, China
| | - Yuntao Song
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Head and Neck Surgery Department, Peking University Cancer Hospital & Institute, Beijing, 100142, China
| | - Guohui Xu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Head and Neck Surgery Department, Peking University Cancer Hospital & Institute, Beijing, 100142, China
| | - Qi Shi
- State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases (Zhejiang University), National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Chang-Bai Rd 155, Beijing, 102206, China.
| | - Xiao-Ping Dong
- State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases (Zhejiang University), National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Chang-Bai Rd 155, Beijing, 102206, China.
| |
Collapse
|
4
|
Li Z, Wei J, Chen B, Wang Y, Yang S, Wu K, Meng X. The Role of MMP-9 and MMP-9 Inhibition in Different Types of Thyroid Carcinoma. Molecules 2023; 28:molecules28093705. [PMID: 37175113 PMCID: PMC10180081 DOI: 10.3390/molecules28093705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Revised: 04/06/2023] [Accepted: 04/11/2023] [Indexed: 05/15/2023] Open
Abstract
Matrix metalloproteinase-9 (MMP-9), one of the most investigated and studied biomarkers of the MMPs family, is a zinc-dependent proteolytic metalloenzyme whose primary function is degrading the extracellular matrix (ECM). It has been proved that MMP-9 expression elevates in multiple pathological conditions, including thyroid carcinoma. MMP-9 has a detectable higher level in malignant or metastatic thyroid tumor tissues than in normal or benign tissues and acts as an additional marker to distinguish different tumor stages because of its close correlations with clinical features, such as lymph node metastasis, TNM stage, tumor size and so on. Natural and non-natural MMP-9 inhibitors suppress its expression, block the progression of diseases, and play a role in therapy consequently. MMP-9 inhibitory molecules also assist in treating thyroid tumors by suppressing the proliferation, invasion, migration, metastasis, viability, adhesion, motility, epithelial-mesenchymal transition (EMT), and other risk factors of different thyroid cancer cells. In a word, discovering and designing MMP-9 inhibitors provide great therapeutic effects and promising clinical values in various types of thyroid carcinoma.
Collapse
Affiliation(s)
- Zhenshengnan Li
- Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, China
| | - Jia Wei
- Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, China
| | - Bowen Chen
- Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, China
| | - Yaoqi Wang
- Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, China
| | - Shuai Yang
- Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, China
| | - Kehui Wu
- Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, China
| | - Xianying Meng
- Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, China
| |
Collapse
|
5
|
Zhang J, Wang J, Yue K, Li P, Shen W, Qiao X, Wang Y, Wu X. FAM83B promotes the invasion of primary lung adenocarcinoma via PI3K/AKT/NF-κB pathway. BMC Pulm Med 2023; 23:32. [PMID: 36690987 PMCID: PMC9872310 DOI: 10.1186/s12890-022-02303-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Accepted: 12/30/2022] [Indexed: 01/24/2023] Open
Abstract
OBJECTS The family with sequence similarity 83B (FAM83B) is one of the markers for poor prognosis in several carcinomas, but the expression and the mechanism resulted in malignant phenotype in lung adenocarcinoma (LUAD) remain to be elucidated. METHODS Data of RNA-seq in LUAD were downloaded from the cancer genome atlas (TCGA) database for differential expression and survival analysis, and immunohistochemistry was employed to analyze the protein expression of FAM83B in 126 cases of primary LUAD. The LUAD cell lines were collected for the detection of the effects on migration and invasion. Then, western blot was performed to measure the expression of tissue inhibitor of metalloproteinase (TIMP)-1 and activation of PI3K/AKT/NF-κB pathway. RESULTS FAM83B was overexpressed in multiple types of carcinomas; The differential expression analysis revealed that the level of FAM83B was higher in LUAD than that in para-carcinoma; The patients with overexpression of FAM83B were with shorter overall survival (OS), disease specific survival (DSS) and progress free interval (PFI); Enrichment analysis suggested it was related to the focal adhesion of LUAD. Immunohistochemistry analysis demonstrated that higher FAM83B expression was positively related to lymph node metastasis in primary. Scratch assay and Borden chamber assay showed that the overexpression of FAM83B promoted migration and invasion activity in vitro. Furthermore, high level of FAM83B accelerated the tumorigenesis in vivo. Western blot showed that TIMP-1 was upregulated in H1299/FAM83B OE cells accompanying by the activation of PI3K/AKT/NF-κB pathway. CONCLUSIONS FAM83B was a marker for poor prognosis of LUAD and it might promote the expression of TIMP-1 by activating PI3K/AKT/NF-κB pathway and then affect the ECM balance, which resulted in the migration and invasion of LUAD.
Collapse
Affiliation(s)
- Jing Zhang
- grid.27255.370000 0004 1761 1174Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012 Shandong China ,grid.27255.370000 0004 1761 1174Department of Pathology, Qilu Hospital, Shandong University, Jinan, 250012 Shandong China
| | - Jiajia Wang
- grid.27255.370000 0004 1761 1174Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012 Shandong China ,grid.27255.370000 0004 1761 1174Department of Pathology, Qilu Hospital, Shandong University, Jinan, 250012 Shandong China
| | - Ke Yue
- grid.27255.370000 0004 1761 1174Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012 Shandong China ,grid.27255.370000 0004 1761 1174Department of Pathology, Qilu Hospital, Shandong University, Jinan, 250012 Shandong China
| | - Panpan Li
- grid.27255.370000 0004 1761 1174Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012 Shandong China ,grid.27255.370000 0004 1761 1174Department of Pathology, Qilu Hospital, Shandong University, Jinan, 250012 Shandong China
| | - Wenping Shen
- grid.27255.370000 0004 1761 1174Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012 Shandong China ,grid.27255.370000 0004 1761 1174Department of Pathology, Qilu Hospital, Shandong University, Jinan, 250012 Shandong China
| | - Xiaowen Qiao
- grid.27255.370000 0004 1761 1174Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012 Shandong China ,grid.27255.370000 0004 1761 1174Department of Pathology, Qilu Hospital, Shandong University, Jinan, 250012 Shandong China
| | - Yan Wang
- grid.27255.370000 0004 1761 1174Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012 Shandong China ,grid.27255.370000 0004 1761 1174Department of Pathology, Qilu Hospital, Shandong University, Jinan, 250012 Shandong China
| | - Xiaojuan Wu
- grid.27255.370000 0004 1761 1174Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012 Shandong China ,grid.27255.370000 0004 1761 1174Department of Pathology, Qilu Hospital, Shandong University, Jinan, 250012 Shandong China
| |
Collapse
|
6
|
Ivković I, Limani Z, Jakovčević A, Huić D, Prgomet D. Role of Matrix Metalloproteinases and Their Inhibitors in Locally Invasive Papillary Thyroid Cancer. Biomedicines 2022; 10:biomedicines10123178. [PMID: 36551933 PMCID: PMC9775144 DOI: 10.3390/biomedicines10123178] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 12/02/2022] [Accepted: 12/06/2022] [Indexed: 12/13/2022] Open
Abstract
Locally invasive papillary thyroid carcinoma (PTC) protrudes beyond the thyroid capsule and invades local structures. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are implicated in local invasion and metastasis in PTC. The aim of our study was to determine expression levels of MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2 in tissue specimens of invasive and non-invasive PTC. Our hypothesis was that expression levels of these biomarkers correlate with the development of locally invasive PTC. In our single-center study we retrospectively investigated MMP and TIMP expression levels in 50 samples of thyroid tissue diagnosed as locally invasive papillary carcinoma (study group) and 30 samples of thyroid tissue diagnosed as non-invasive, non-metastatic papillary carcinoma (control group). Tissue specimens were immunohistochemically stained with primary monoclonal antibodies against MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2. When correlating expression levels of MMPs and TIMPs in thyroid tissue, statistically significant differences were found for MMP-1 and TIMP-1 expression (p < 0.001; Mann−Whitney U test) with the highest levels of expression in the invasive PTC group. Although expression of MMP-9 and TIMP-2 was higher in invasive PTC, the differences were not statistically significant. Elevated expression of MMP-1 and TIMP-1 in tumor tissue can predict invasiveness for PTC.
Collapse
Affiliation(s)
- Irena Ivković
- Department of Otorhinolaryngology-Head & Neck Surgery, School of Medicine Zagreb, University Hospital Centre Zagreb, 10 000 Zagreb, Croatia
| | - Zgjim Limani
- Department of ENT-Head & Neck Surgery, University Clinical Center of Kosovo, 10 000 Prishtina, Kosovo
- Faculty of Medicine, University of Prishtina “Hasan Prishtina”, 10 000 Prishtina, Kosovo
- Correspondence: ; Tel.: +383-44-173-379
| | - Antonia Jakovčević
- Department of Pathology and Cytology, University Hospital Centre Zagreb, 10 000 Zagreb, Croatia
| | - Dražen Huić
- Department of Nuclear Medicine and Radiation Protection, School of Medicine Zagreb, University Hospital Centre Zagreb, 10 000 Zagreb, Croatia
| | - Drago Prgomet
- Department of Otorhinolaryngology-Head & Neck Surgery, School of Medicine Zagreb, University Hospital Centre Zagreb, 10 000 Zagreb, Croatia
| |
Collapse
|
7
|
Zhou J, Xu M, Tan J, Zhou L, Dong F, Huang T. MMP1 acts as a potential regulator of tumor progression and dedifferentiation in papillary thyroid cancer. Front Oncol 2022; 12:1030590. [DOI: 10.3389/fonc.2022.1030590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Accepted: 10/26/2022] [Indexed: 11/22/2022] Open
Abstract
Papillary thyroid cancer (PTC) is one of the malignancies with an excellent prognosis. However, in PTC, progression or dedifferentiation into poorly differentiated thyroid cancer (PDTC) or anaplastic thyroid cancer (ATC) extremely jeopardizes patients’ prognosis. MMP1 is a zinc-dependent endopeptidase, and its role in PTC progression and dedifferentiation is unclear. In this study, transcriptome data of PDTC/ATC and PTC from the Gene Expression Omnibus and The Cancer Genome Atlas databases were utilized to perform an integrated analysis of MMP1 as a potential regulator of tumor progression and dedifferentiation in PTC. Both bulk and single-cell RNA-sequencing data confirmed the high expression of MMP1 in ATC tissues and cells, and further study verified that MMP1 possessed good diagnostic and prognostic value in PTC and PDTC/ATC. Up-regulated MMP1 was found to be positively related to more aggressive clinical characteristics, worse survival, extracellular matrix-related pathways, oncogenic immune microenvironment, more mutations, higher stemness, and more dedifferentiation of PTC. Meanwhile, in vitro experiments verified the high level of MMP1 in PDTC/ATC cell lines, and MMP1 knockdown and its inhibitor triolein could both inhibit the cell viability of PTC and PDTC/ATC. In conclusion, our findings suggest that MMP1 is a potential regulator of tumor progression and dedifferentiation in PTC, and might become a novel therapeutic target for PTC, especially for more aggressive PDTC and ATC.
Collapse
|
8
|
Predictive Significance of Two MMP-9 Promoter Polymorphisms and Acetylated c-Jun Transcription Factor for Papillary Thyroid Carcinoma Advancement. Diagnostics (Basel) 2022; 12:diagnostics12081953. [PMID: 36010303 PMCID: PMC9406990 DOI: 10.3390/diagnostics12081953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Revised: 07/26/2022] [Accepted: 08/06/2022] [Indexed: 11/27/2022] Open
Abstract
Papillary thyroid carcinoma represents a challenge from a prognostic standpoint. Molecular alterations responsible for PTC advancement include MMP-9 genetic promoter polymorphisms that bind transcription factors with varying degrees of affinity and, hence, constitute a predisposition for MMP-9 expression. We examined how two promoter polymorphisms (the -1562 C/T transition and -131 (CA)n tandem repeats) as well as levels of the c-Jun transcription factor and its modified form acetylated at Lys271 influence MMP-9 expression and PTC progression. A significant proportion of PTC samples were heterozygous for the (CA)n tandem repeat number, had a transcription-promoting T allele at -1562, and expressed high levels of c-Jun, acetylated c-Jun, and MMP-9 protein. The T allele at the -1562 position accompanied the elevated MMP-9 protein expression, while high acetylated c-Jun levels accompanied the high MMP-9 protein levels on mRNA. The -1562 C/T transition, MMP-9, and acetylated c-Jun were associated with the presence of extra-thyroid invasion and degree of tumor infiltration, while the T allele and acetylated c-Jun also correlated with tumor stage. We conclude that the -1562 MMP-9 polymorphism and levels of acetylated c-Jun affect PTC progression via modulation of MMP-9 levels. Genotyping the MMP-9 at -1562 and estimating the levels of MMP-9 and acetylated c-Jun in PTC may prove beneficial in identifying high-risk patients.
Collapse
|
9
|
Niciporuka R, Nazarovs J, Ozolins A, Narbuts Z, Miklasevics E, Gardovskis J. Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers. MEDICINA (KAUNAS, LITHUANIA) 2021; 57:1131. [PMID: 34684168 PMCID: PMC8540789 DOI: 10.3390/medicina57101131] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 09/19/2021] [Revised: 10/07/2021] [Accepted: 10/15/2021] [Indexed: 12/27/2022]
Abstract
Thyroid cancer is ranked in ninth place among all the newly diagnosed cancer cases in 2020. Differentiated thyroid cancer behavior can vary from indolent to extremely aggressive. Currently, predictions of cancer prognosis are mainly based on clinicopathological features, which are direct consequences of cell and tissue microenvironment alterations. These alterations include genetic changes, cell cycle disorders, estrogen receptor expression abnormalities, enhanced epithelial-mesenchymal transition, extracellular matrix degradation, increased hypoxia, and consecutive neovascularization. All these processes are represented by specific genetic and molecular markers, which can further predict thyroid cancer development, progression, and prognosis. In conclusion, evaluation of cancer genetic and molecular patterns, in addition to clinicopathological features, can contribute to the identification of patients with a potentially worse prognosis. It is essential since it plays a crucial role in decision-making regarding initial surgery, postoperative treatment, and follow-up. To date, there is a large diversity in methodologies used in different studies, frequently leading to contradictory results. To evaluate the true significance of predictive markers, more comparable studies should be conducted.
Collapse
Affiliation(s)
- Rita Niciporuka
- Department of Surgery, Riga Stradins University, Pilsonu Street 13, LV-1002 Riga, Latvia; (A.O.); (Z.N.); (J.G.)
- Department of Surgery, Pauls Stradins Clinical University Hospital, Pilsonu Street 13, LV-1002 Riga, Latvia
| | - Jurijs Nazarovs
- Department of Pathology, Pauls Stradins Clinical University Hospital, Pilsonu Street 13, LV-1002 Riga, Latvia;
| | - Arturs Ozolins
- Department of Surgery, Riga Stradins University, Pilsonu Street 13, LV-1002 Riga, Latvia; (A.O.); (Z.N.); (J.G.)
- Department of Surgery, Pauls Stradins Clinical University Hospital, Pilsonu Street 13, LV-1002 Riga, Latvia
| | - Zenons Narbuts
- Department of Surgery, Riga Stradins University, Pilsonu Street 13, LV-1002 Riga, Latvia; (A.O.); (Z.N.); (J.G.)
- Department of Surgery, Pauls Stradins Clinical University Hospital, Pilsonu Street 13, LV-1002 Riga, Latvia
| | - Edvins Miklasevics
- Institute of Oncology, Riga Stradins University, Pilsonu Street 13, LV-1002 Riga, Latvia;
| | - Janis Gardovskis
- Department of Surgery, Riga Stradins University, Pilsonu Street 13, LV-1002 Riga, Latvia; (A.O.); (Z.N.); (J.G.)
- Department of Surgery, Pauls Stradins Clinical University Hospital, Pilsonu Street 13, LV-1002 Riga, Latvia
| |
Collapse
|
10
|
Gršić K, Bumber B, Curić Radivojević R, Leović D. Prophylactic Central Neck Dissection in Well-differentiated Thyroid Cancer. Acta Clin Croat 2021; 59:87-95. [PMID: 34219889 PMCID: PMC8212603 DOI: 10.20471/acc.2020.59.s1.11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Well-differentiated cancers, both papillary and follicular, account for 90% of all diagnosed thyroid cancers. They have an indolent disease course with a 20-year disease-specific survival over 90%. According to current guidelines, the therapy of choice for well-differentiated thyroid carcinoma is total thyroidectomy or lobectomy. The indication for prophylactic central neck dissection is still a controversial issue and the subject of unfinished and ongoing debate. There is no indication for prophylactic central neck dissection in follicular thyroid carcinomas, which primarily metastasize hematogenously. In small solitary papillary thyroid carcinomas (T1 and T2), prophylactic central neck dissection is not indicated as it does not bring benefits in terms of improved patient survival and at the same time significantly increases the risk of temporary and permanent postoperative complications. Prophylactic central neck dissection is indicated in advanced papillary thyroid cancers (T3 and T4) and all other high-risk well-differentiated thyroid cancer, as well as in the presence of metastatic lymph nodes in the lateral neck.
Collapse
Affiliation(s)
| | - Boris Bumber
- 1Department of Otorhinolaryngology and head and neck surgery, Zagreb University Hospital Centre, Zagreb, Croatia; 2Department of Anaesthesiology, Resuscitation and Intensive Care, Zagreb University Hospital Centre, Zagreb, Croatia; 3Department of Otorhinolaryngology and Maxillofacial Surgery, Faculty of Medicine, J. J. Strossmayer University of Osijek, Osijek, Croatia; 4Department of Dental Medicine, Faculty of Dental Medicine and Health, J. J. Strossmayer University of Osijek, Osijek, Croatia
| | - Renata Curić Radivojević
- 1Department of Otorhinolaryngology and head and neck surgery, Zagreb University Hospital Centre, Zagreb, Croatia; 2Department of Anaesthesiology, Resuscitation and Intensive Care, Zagreb University Hospital Centre, Zagreb, Croatia; 3Department of Otorhinolaryngology and Maxillofacial Surgery, Faculty of Medicine, J. J. Strossmayer University of Osijek, Osijek, Croatia; 4Department of Dental Medicine, Faculty of Dental Medicine and Health, J. J. Strossmayer University of Osijek, Osijek, Croatia
| | - Dinko Leović
- 1Department of Otorhinolaryngology and head and neck surgery, Zagreb University Hospital Centre, Zagreb, Croatia; 2Department of Anaesthesiology, Resuscitation and Intensive Care, Zagreb University Hospital Centre, Zagreb, Croatia; 3Department of Otorhinolaryngology and Maxillofacial Surgery, Faculty of Medicine, J. J. Strossmayer University of Osijek, Osijek, Croatia; 4Department of Dental Medicine, Faculty of Dental Medicine and Health, J. J. Strossmayer University of Osijek, Osijek, Croatia
| |
Collapse
|
11
|
Abičić I, Prpić T, Bogović V, Milanković SG, Mihalj H, Včeva A, Zubčić Ž, Šestak A, Rezo M. Characteristics of Malignant Thyroid Tumors: A Retrospective Study on 320 Patients. Acta Clin Croat 2021; 59:108-114. [PMID: 34219892 PMCID: PMC8212610 DOI: 10.20471/acc.2020.59.s1.14] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Papillary thyroid cancer accounts for 80-85% of diagnosed thyroid cancers, while follicular, medullary, and anaplastic cancers are diagnosed significantly less frequently. This study aimed to show the characteristics of malignant thyroid tumors. In this retrospective study, we analyzed data from 320 patients who underwent thyroid surgery from January 2018 to December 2019. We recorded and statistically analyzed basic demographic data, data of the cytological and pathohistological findings, and tumor characteristics (size, multifocality, extrathyroidal and lymphovascular invasion). Thyroid cancer was diagnosed in 95 patients. The incidence of thyroid cancer was higher in women than in men, but without a significant difference (p=0.46). There was a significant difference between preoperative cytological findings and definitive pathohistological diagnosis (p=0.001). There was no significant difference between genders in tumor size, extrathyroidal and lymphovascular invasion, and multifocality. There were significantly more thyroid cancers with a lymphovascular invasion that were less than 2 cm in size (p=0.04). In our opinion, it is important to emphasize the value of early diagnostics and analysis of the malignant tumor characteristics that are major prognostic factors for survival in patients with thyroid cancer.
Collapse
Affiliation(s)
- Ivan Abičić
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, J.J. Strossmayer Osijek University, J. Huttlera 4, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, J. Huttlera 4, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Županijska ul. 35, Vukovar, Croatia
| | - Tin Prpić
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, J.J. Strossmayer Osijek University, J. Huttlera 4, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, J. Huttlera 4, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Županijska ul. 35, Vukovar, Croatia
| | - Vjeran Bogović
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, J.J. Strossmayer Osijek University, J. Huttlera 4, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, J. Huttlera 4, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Županijska ul. 35, Vukovar, Croatia
| | - Stjepan Grga Milanković
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, J.J. Strossmayer Osijek University, J. Huttlera 4, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, J. Huttlera 4, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Županijska ul. 35, Vukovar, Croatia
| | - Hrvoje Mihalj
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, J.J. Strossmayer Osijek University, J. Huttlera 4, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, J. Huttlera 4, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Županijska ul. 35, Vukovar, Croatia
| | - Andrijana Včeva
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, J.J. Strossmayer Osijek University, J. Huttlera 4, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, J. Huttlera 4, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Županijska ul. 35, Vukovar, Croatia
| | - Željko Zubčić
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, J.J. Strossmayer Osijek University, J. Huttlera 4, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, J. Huttlera 4, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Županijska ul. 35, Vukovar, Croatia
| | - Anamarija Šestak
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, J.J. Strossmayer Osijek University, J. Huttlera 4, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, J. Huttlera 4, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Županijska ul. 35, Vukovar, Croatia
| | - Matej Rezo
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, J.J. Strossmayer Osijek University, J. Huttlera 4, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, J. Huttlera 4, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Županijska ul. 35, Vukovar, Croatia
| |
Collapse
|
12
|
Ding J, Wang X, Gao J, Song T. Silencing of cystatin SN abrogates cancer progression and stem cell properties in papillary thyroid carcinoma. FEBS Open Bio 2021. [PMID: 34102026 PMCID: PMC8329778 DOI: 10.1002/2211-5463.13221] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Revised: 03/29/2021] [Accepted: 06/07/2021] [Indexed: 01/03/2023] Open
Abstract
Papillary thyroid carcinoma (PTC) accounts for approximately 80% of total thyroid cancers worldwide. Although the prognosis for early‐stage PTC is favorable, the 5‐year survival rate of patients with late‐stage PTC is still very poor. Cystatin SN (cystatin 1, CST1) facilitates the progression of multiple cancers, but its role in regulating PTC pathogenesis is still largely unknown. In this study, we measured the expression levels of CST1 in PTC clinical tissues and cell lines by real‐time quantitative PCR and western blot analysis, and we performed gain‐ and loss‐of‐function experiments to examine the effects of CST1 on PTC cell growth, invasion, migration, epithelial–mesenchymal transition and stemness. Tumorigenicity was assessed using in vivo tumor‐bearing nude mouse models. As expected, upregulated CST1 was observed in PTC tissues (P < 0.05) and cells, compared with their normal counterparts (P < 0.05); furthermore, patients with PTC with higher levels of CST1 exhibited unfavorable prognosis (P < 0.05). In addition, CST1 ablation inhibited PTC cell growth (P < 0.05) in vivo and in vitro. Silencing of CST1 also inhibited cell motility and epithelial–mesenchymal transition in PTC cells (P < 0.05), whereas CST1 overexpression had the opposite effects on the earlier cellular functions. Notably, up‐regulation of CST1 promoted cell spheroid formation (P < 0.05) and increased the expression levels of stemness signatures (P < 0.05) in PTC cells. Collectively, these findings suggest that CST1 functions as an oncogene to facilitate cancer development and promote cancer stem cell properties in PTC cells, increasing our understanding of PTC pathogenesis mechanisms and possibly aiding in the development of potential therapeutic strategies.
Collapse
Affiliation(s)
- Jiaojiao Ding
- Department of Ultrasound, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
| | - Xiaorong Wang
- Department of Ultrasound, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
| | - Junxi Gao
- Department of Ultrasound, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
| | - Tao Song
- Department of Ultrasound, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
| |
Collapse
|
13
|
Melaccio A, Sgaramella LI, Pasculli A, Di Meo G, Gurrado A, Prete FP, Vacca A, Ria R, Testini M. Prognostic and Therapeutic Role of Angiogenic Microenvironment in Thyroid Cancer. Cancers (Basel) 2021; 13:cancers13112775. [PMID: 34204889 PMCID: PMC8199761 DOI: 10.3390/cancers13112775] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Revised: 05/29/2021] [Accepted: 05/31/2021] [Indexed: 12/15/2022] Open
Abstract
Simple Summary Angiogenesis is an essential event for the progression of solid tumors and is promoted by angiogenic cytokines released in the tumor microenvironment by neoplastic and stromal cells. Over the last 20 years, the role of the microenvironment and the implication of several angiogenic factors in tumorigenesis of solid and hematological neoplasms have been widely studied. The tumor microenvironment has also been well-defined for thyroid cancer, clarifying the importance of angiogenesis in cancer progression, spread, and metastasis. Furthermore, recent studies have evaluated the association of circulating angiogenic factors with the clinical outcomes of differentiated thyroid cancer, potentially providing noninvasive, low-cost, and safe tests that can be used in screening, diagnosis, and follow-up. In this review, we highlight the mechanisms of action of these proangiogenic factors and their different molecular pathways, as well as their applications in the treatment and prognosis of thyroid cancer. Abstract Thyroid cancer is the most common endocrine malignancy, with a typically favorable prognosis following standard treatments, such as surgical resection and radioiodine therapy. A subset of thyroid cancers progress to refractory/metastatic disease. Understanding how the tumor microenvironment is transformed into an angiogenic microenvironment has a role of primary importance in the aggressive behavior of these neoplasms. During tumor growth and progression, angiogenesis represents a deregulated biological process, and the angiogenic switch, characterized by the formation of new vessels, induces tumor cell proliferation, local invasion, and hematogenous metastases. This evidence has propelled the scientific community’s effort to study a number of molecular pathways (proliferation, cell cycle control, and angiogenic processes), identifying mediators that may represent viable targets for new anticancer treatments. Herein, we sought to review angiogenesis in thyroid cancer and the potential role of proangiogenic cytokines for risk stratification of patients. We also present the current status of treatment of advanced differentiated, medullary, and poorly differentiated thyroid cancers with multiple tyrosine kinase inhibitors, based on the rationale of angiogenesis as a potential therapeutic target.
Collapse
Affiliation(s)
- Assunta Melaccio
- Operative Unit of Internal Medicine “G. Baccelli”, Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro” Medical School, 70124 Bari, Italy; (A.M.); (A.V.); (R.R.)
| | - Lucia Ilaria Sgaramella
- Academic General Surgery Unit “V. Bonomo”, Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro” Medical School, 70124 Bari, Italy; (L.I.S.); (A.P.); (G.D.M.); (A.G.); (F.P.P.)
| | - Alessandro Pasculli
- Academic General Surgery Unit “V. Bonomo”, Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro” Medical School, 70124 Bari, Italy; (L.I.S.); (A.P.); (G.D.M.); (A.G.); (F.P.P.)
| | - Giovanna Di Meo
- Academic General Surgery Unit “V. Bonomo”, Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro” Medical School, 70124 Bari, Italy; (L.I.S.); (A.P.); (G.D.M.); (A.G.); (F.P.P.)
| | - Angela Gurrado
- Academic General Surgery Unit “V. Bonomo”, Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro” Medical School, 70124 Bari, Italy; (L.I.S.); (A.P.); (G.D.M.); (A.G.); (F.P.P.)
| | - Francesco Paolo Prete
- Academic General Surgery Unit “V. Bonomo”, Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro” Medical School, 70124 Bari, Italy; (L.I.S.); (A.P.); (G.D.M.); (A.G.); (F.P.P.)
| | - Angelo Vacca
- Operative Unit of Internal Medicine “G. Baccelli”, Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro” Medical School, 70124 Bari, Italy; (A.M.); (A.V.); (R.R.)
| | - Roberto Ria
- Operative Unit of Internal Medicine “G. Baccelli”, Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro” Medical School, 70124 Bari, Italy; (A.M.); (A.V.); (R.R.)
| | - Mario Testini
- Academic General Surgery Unit “V. Bonomo”, Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro” Medical School, 70124 Bari, Italy; (L.I.S.); (A.P.); (G.D.M.); (A.G.); (F.P.P.)
- Correspondence: ; Tel.: +39-3355370914
| |
Collapse
|
14
|
Pan Q, Yuan T, Ding Q. Clinical value of matrix metalloproteinase-2 and -9 in ultrasound-guided radiofrequency ablation treatment for papillary thyroid carcinoma. J Int Med Res 2021; 48:300060520917581. [PMID: 32772889 PMCID: PMC7418228 DOI: 10.1177/0300060520917581] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
OBJECTIVE This study aimed to investigate serum matrix metalloproteinase (MMP)-2 and MMP-9 levels in patients with papillary thyroid carcinoma (PTC). METHODS Forty-one patients with PTC undergoing ultrasound-guided radiofrequency ablation (RFA) and 56 controls were included. Serum MMP-2 and MMP-9 levels were determined by enzyme-linked immunosorbent assay before and after surgery. Potential affecting factors were evaluated by logistic regression analysis. RESULTS Serum MMP-2 and MMP-9 levels were significantly higher in PTC patients compared with controls, and decreased significantly after surgery. According to receiver operating characteristic curve analysis, diagnostic values for preoperative serum MMP-2 and MMP-9 levels were 82.4% and 86.6%. There was no contrast-agent perfusion in the ablation zone in 88.5% of lesions, and enhancement within or at the lesion edge in 11.4%. The volume reduction at 3 months' follow-up was >40%. Age, microcalcification, irregular shape, and lesion diameter and number were influencing factors for PTC. Age, and lesion diameter and number were independent risk factors, while calcification and morphology were protective factors. CONCLUSION Serum MMP-2 and MMP-9 levels have important clinical values for the diagnosis and treatment of PTC by RFA. Preoperative serum MMP-2 and MMP-9 levels, combined with other affecting factors, contribute to disease prognosis.
Collapse
Affiliation(s)
- Qunyan Pan
- Department of Ultrasound, Beilun People's Hospital of Ningbo, Beilun Branch of the First Affiliated Hospital of Zhejiang University, Ningbo, Zhejiang, China
| | - Tao Yuan
- Department of Ultrasound, Beilun People's Hospital of Ningbo, Beilun Branch of the First Affiliated Hospital of Zhejiang University, Ningbo, Zhejiang, China
| | - Qian Ding
- Department of Ultrasound, Beilun People's Hospital of Ningbo, Beilun Branch of the First Affiliated Hospital of Zhejiang University, Ningbo, Zhejiang, China
| |
Collapse
|
15
|
MacDonald L, Jenkins J, Purvis G, Lee J, Franco AT. The Thyroid Tumor Microenvironment: Potential Targets for Therapeutic Intervention and Prognostication. Discov Oncol 2020; 11:205-217. [PMID: 32548798 DOI: 10.1007/s12672-020-00390-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 06/11/2020] [Indexed: 12/13/2022] Open
Abstract
Thyroid cancer is the most common endocrine malignancy and incidences are rising rapidly, in both pediatric and adult populations. Many thyroid tumors are successfully treated which results in low mortality rates, but there is often a significant morbidity associated with thyroid cancer treatments. For patients with tumors that are not successfully treated with surgical resection or radioactive iodine treatment, prognosis is dramatically reduced. Patients diagnosed with anaplastic thyroid cancer face a very grim prognosis with a median survival of 6 months post-diagnosis. There is a critical need to identify patients who are at greatest risk of developing persistent disease and progressing to poorly differentiated or anaplastic disease. Furthermore, development of treatments associated with less morbidity would represent a significant improvement for thyroid cancer survivors. It is well established the stromal cells and components of the tumor microenvironment can drive tumor progression and resistance to therapy. Here we review the current state of what is known regarding the thyroid tumor microenvironment and how these factors may contribute to thyroid tumor pathogenesis. Study of the tumor microenvironment within thyroid cancer is a relatively new field, and more studies are needed to dissect the complex and dynamic crosstalk between thyroid tumor cells and its tumor niche.
Collapse
Affiliation(s)
| | | | - Grace Purvis
- Division of Endocrinology and Diabetes Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Joshua Lee
- Division of Endocrinology and Diabetes Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Aime T Franco
- Division of Endocrinology and Diabetes Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
| |
Collapse
|
16
|
Miličić B, Prstačić R, Prgomet D. Skip Metastases in Papillary Thyroid Carcinoma - Prevalence, Predictive and Clinicopathological Factors. Acta Clin Croat 2020; 59:122-128. [PMID: 34219894 PMCID: PMC8212598 DOI: 10.20471/acc.2020.59.s1.16] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background Cervical lymph node metastases are frequently found in papillary thyroid carcinoma (PTC) and occur in a stepwise fashion. Skip metastases that omit the central compartment and spread initially in lateral neck levels are present in a certain share of patients, and their significance is poorly understood. The aim of this prospective study was to identify their possible predictors and clinicopathological factors in a group of patients with PTC with lateral lymph node (LLN) metastases. Methods We enrolled 68 patients with PTC with preoperatively evaluated LLN metastases who underwent total thyroidectomy with lateral lymph node dissection between 2011 and 2018. We analysed the clinicopathological features and pattern of dissemination of continuous and skip metastases. Results The prevalence of skip metastases was 23.5%. Compared with the continuous metastases group, the patients were older, had primary tumors that were more often situated unilaterally, and had smaller primary tumor size. Level II was less often involved, and none of the patients with skip metastases had all LNN positive (p = 0.05). Conclusion Skip metastases occur more frequently in older patients and display certain clinicopathological features like smaller size of the primary tumor and dissemination in less lateral neck levels. In the view of the fact that they are found rather frequently, lateral neck regions should be meticulously investigated in patients with PTC without central lymph node (CLL) metastases.
Collapse
Affiliation(s)
| | - Ratko Prstačić
- 1Department of Ear, Nose, Throat, and Head and Neck Surgery, Zagreb University Hospital Centre; 2School of Medicine, University of Zagreb
| | - Drago Prgomet
- 1Department of Ear, Nose, Throat, and Head and Neck Surgery, Zagreb University Hospital Centre; 2School of Medicine, University of Zagreb
| |
Collapse
|
17
|
Zubčić Ž, Šestak A, Mihalj H, Kotromanović Ž, Včeva A, Prpić T, Rezo M, Milanković SG, Bogović V, Abičić I. The AsSociation Between Type 2 Diabetes Mellitus, Hypothyroidism, and Thyroid Cancer. Acta Clin Croat 2020; 59:129-135. [PMID: 34219895 PMCID: PMC8212611 DOI: 10.20471/acc.2020.59.s1.17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
This study aimed to investigate the association between type 2 diabetes mellitus (T2DM), antidiabetic therapy, hypothyroidism, and thyroid cancer. We analyzed data from 320 patients who underwent thyroid surgery for suspicion of cancer. The diagnosis of thyroid cancer was confirmed by histopathological analysis in 95 patients. No significant difference was found in the diagnosis of T2DM and hypothyroidism concerning the presence of thyroid cancer (p=0.13; p=0.85), nor in the gender of patients with T2DM and hypothyroidism with respect to the type of thyroid cancer (p=0.19; p=0.25). Patients with T2DM (Odds ratio [OR] 1.89; 95% CI, 0.856-4.163) and patients with hypothyroidism (OR, 1.05; 95% CI, 0.530-2.164) had higher prevalence of thyroid cancer, as did those who had both diagnoses combined (p=0.37; OR, 2.39; 95% CI, 0.333-17.278), compared with the patients who did not have those diagnoses. Men with T2DM (OR, 6.19; 95% CI, 1.180-32.513) had higher prevalence of thyroid cancer than women. Patients who were on oral antidiabetics (OR, 1.91; 95% CI, 0.804-4.512) had higher prevalence of thyroid cancer than those receiving insulin. According to the results of this study, we can conclude that there is an association between T2DM, hypothyroidism, oral antidiabetics, and thyroid cancer.
Collapse
Affiliation(s)
| | - Anamarija Šestak
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, University J.J. Strossmayer Osijek, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Vukovar, Croatia
| | - Hrvoje Mihalj
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, University J.J. Strossmayer Osijek, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Vukovar, Croatia
| | - Željko Kotromanović
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, University J.J. Strossmayer Osijek, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Vukovar, Croatia
| | - Andrijana Včeva
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, University J.J. Strossmayer Osijek, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Vukovar, Croatia
| | - Tin Prpić
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, University J.J. Strossmayer Osijek, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Vukovar, Croatia
| | - Matej Rezo
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, University J.J. Strossmayer Osijek, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Vukovar, Croatia
| | - Stjepan Grga Milanković
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, University J.J. Strossmayer Osijek, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Vukovar, Croatia
| | - Vjeran Bogović
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, University J.J. Strossmayer Osijek, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Vukovar, Croatia
| | - Ivan Abičić
- 1Department of Otorhinolaryngology and Maxillofacial Surgery, Osijek Medical Faculty, University J.J. Strossmayer Osijek, Osijek, Croatia; 2Department of Otorhinolaryngology and Head and Neck Surgery, Osijek Clinical Hospital Centre, Osijek, Croatia; 3Department of Otorhinolaryngology, Vukovar General Hospital, Vukovar, Croatia
| |
Collapse
|
18
|
Stubljar B, Pastorčić Grgić M, Mayer L, Perše P, Tomičević T. Elective Central Compartment Lymph Node Dissection Does not Increase the Risk of Postoperative Hypoparathyroidism in Patients Treated for Differentiated Thyroid Cancer. Acta Clin Croat 2020; 59:115-121. [PMID: 34219893 PMCID: PMC8212604 DOI: 10.20471/acc.2020.59.s1.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Aim The aim of this study was to compare the incidence of postoperative hypoparathyroidism in two groups of patients who were treated for differentiated thyroid cancer. Methods A retrospective analysis of 179 patients who were treated for differentiated thyroid cancer in our institution from January 2011 until December 2018 was performed. Only patients initially treated with total thyroidectomy and those who did not have preoperatively confirmed central compartment and lateral neck lymph node metastases were included in this study. Two main groups of patients were analysed. The patients who were treated with total thyroidectomy and elective central compartment lymph node dissection simultaneously were included in the first group. The patients who were treated only with total thyroidectomy were included in the second group. The rate of transitory and persistent postoperative hypoparathyroidism was compared between the two groups. Results A total of 117 patients (65.4%) underwent total thyroidectomy and elective central compartment lymph node dissection simultaneously (TT + CCLNd group). The remaining 62 patients (34.6%) underwent total thyroidectomy only (TT group). A total of 22.6% patients in the TT group developed postoperative hypoparathyroidism compared with 25.6% in the TT + CCLNd group. The rate of persistent hypoparathyroidism in the TT and TT + CCLNd groups was 3.2% and 6.0%, respectively. The difference in the rate of transient and persistent postoperative hypoparathyroidism was not statistically significant between the two groups. Within the TT + CCLNd group, 82.9% of patients underwent ipsilateral paratracheal lymph node dissection and 17.1% underwent bilateral paratracheal lymph node dissection. The rate of postoperative hypoparathyroidism was analysed in those two subgroups of patients and did not prove to be statistically significant. Discussion While its impact on the local recurrence rate is still controversial, elective central compartment lymph node dissection could be a great tool for selection of patients who could profit from adjuvant radioiodine treatment. On the other hand, central compartment lymph node dissection could potentially increase the risk of hypoparathyroidism due to involuntary injury to parathyroid glands and/or their blood supply. Our study did not find a statistically significant difference regarding postoperative hypoparathyroidism between patients who underwent central compartment lymph node dissection compared with patients who underwent total thyroidectomy only. Our data are not in accordance with some of the previously published studies. Conclusion Our results demonstrated that elective central compartment lymph node dissection is a safe procedure and does not significantly increase the risk of postoperative hypoparathyroidism when it is performed simultaneously with total thyroidectomy.
Collapse
Affiliation(s)
| | - Marija Pastorčić Grgić
- 1Division of Head and Neck Surgery, Department of Surgical Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre; 2Laboratory Diagnostics Division, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre
| | - Ljiljana Mayer
- 1Division of Head and Neck Surgery, Department of Surgical Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre; 2Laboratory Diagnostics Division, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre
| | - Pavao Perše
- 1Division of Head and Neck Surgery, Department of Surgical Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre; 2Laboratory Diagnostics Division, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre
| | - Tomislav Tomičević
- 1Division of Head and Neck Surgery, Department of Surgical Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre; 2Laboratory Diagnostics Division, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre
| |
Collapse
|
19
|
Bogović Crnčić T, Ilić Tomaš M, Girotto N, Grbac Ivanković S. Risk Factors for Thyroid Cancer: What Do We Know So Far? Acta Clin Croat 2020; 59:66-72. [PMID: 34219886 PMCID: PMC8212601 DOI: 10.20471/acc.2020.59.s1.08] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Thyroid cancer (TC) is the most common endocrine cancer today. The rising incidence of the differentiated papillary type cannot be entirely explained by early and meticulous diagnosis, since a proportion of large tumors has also been reported. In this review, we present the results of numerous investigations focused on possible factors causing increased TC incidence, such as chromosomal and genetic alterations, iodine intake, TSH level, autoimmune thyroid disease, gender, estrogen, obesity, lifestyle changes, and environmental pollutants. Up to now, only childhood exposure to ionizing radiation has been fully recognized as a risk factor. There is also a possibility that yet undiscovered carcinogens, especially during intrauterine life or early childhood, might be responsible for increased TC incidence as well as epigenetic changes. Therefore, more studies are necessary in order to further investigate the potential risk factors for TC and their mechanisms of action.
Collapse
Affiliation(s)
| | - Maja Ilić Tomaš
- Department of Nuclear Medicine, University of Rijeka Faculty of Medicine, Clinical Department of Nuclear Medicine, Rijeka Clinical Hospital Centre, Rijeka, Croatia
| | - Neva Girotto
- Department of Nuclear Medicine, University of Rijeka Faculty of Medicine, Clinical Department of Nuclear Medicine, Rijeka Clinical Hospital Centre, Rijeka, Croatia
| | - Svjetlana Grbac Ivanković
- Department of Nuclear Medicine, University of Rijeka Faculty of Medicine, Clinical Department of Nuclear Medicine, Rijeka Clinical Hospital Centre, Rijeka, Croatia
| |
Collapse
|
20
|
Pastorčić Grgić M, Stubljar B, Perše P, Zekan Vučetić M, Šitić S. Total Thyroidectomy with Central Node Dissection is a Valuable Option in Papillary Thyroid Cancer Treatment. Acta Clin Croat 2020; 59:102-107. [PMID: 34219891 PMCID: PMC8212608 DOI: 10.20471/acc.2020.59.s1.13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Introduction Papillary thyroid cancer is one of the cancers with favorable prognosis, although the long-term recurrence rate in the paratracheal region is reported to be as high as 30%. The use of 131I is considered to be a reliable treatment option for lymph node metastases in the paratracheal region. According to the majority of internationally accepted guidelines, it is not recommended to perform central node dissection (CND) routinely. Total thyroidectomy (TT) remains an adequate treatment for these patients. According to many studies, CND is associated with higher rates of hypoparathyroidism. However, CND improves staging. Methods We performed a retrospective study. We included 248 patients treated for papillary thyroid cancer during a 20-year period. Data were collected on patient (age, sex) and tumor (size, focality) characteristics, presence of metastases in the central neck compartment, incidence of postoperative hypoparathyroidism, and locoregional failure. We divided patients into two groups based on pathological analysis: those without positive lymph nodes (N0) and those with positive paratracheal lymph nodes (N1). We compared patient and tumor characteristics and risk of recurrence between the two groups. Results: There were 39.5% patients with central neck metastases in our series. In the central neck dissection specimen, 5.5 nodes were found on average. Hypoparathyroidism was found in 23.4% of patients and remained permanent in 3.2% of patients. Female and older patients had a lower chance of central compartment metastases, as did patients with smaller and unifocal tumors. Recurrence risk was doubled for the N1 group. All tested differences between the groups reached statistical significance. Discussion and conclusion In our hands, CND was a safe and effective surgical procedure. It improved staging and postsurgical management. Efforts should be made to improve the preoperative work-up in order to more accurately identify high-risk patients.
Collapse
Affiliation(s)
| | - Boris Stubljar
- 1Division of Head and Neck Surgery, Department of Surgical Oncology, University Hospital for Tumors, "Sestre milosrdnice" University Hospital Centre; 2Division of Radiology, University Hospital for Tumors, "Sestre milosrdnice" University Hospital Centre; 3Division of Pathology, University Hospital for Tumors, "Sestre milosrdnice" University Hospital Centre
| | - Pavao Perše
- 1Division of Head and Neck Surgery, Department of Surgical Oncology, University Hospital for Tumors, "Sestre milosrdnice" University Hospital Centre; 2Division of Radiology, University Hospital for Tumors, "Sestre milosrdnice" University Hospital Centre; 3Division of Pathology, University Hospital for Tumors, "Sestre milosrdnice" University Hospital Centre
| | - Mirta Zekan Vučetić
- 1Division of Head and Neck Surgery, Department of Surgical Oncology, University Hospital for Tumors, "Sestre milosrdnice" University Hospital Centre; 2Division of Radiology, University Hospital for Tumors, "Sestre milosrdnice" University Hospital Centre; 3Division of Pathology, University Hospital for Tumors, "Sestre milosrdnice" University Hospital Centre
| | - Sanda Šitić
- 1Division of Head and Neck Surgery, Department of Surgical Oncology, University Hospital for Tumors, "Sestre milosrdnice" University Hospital Centre; 2Division of Radiology, University Hospital for Tumors, "Sestre milosrdnice" University Hospital Centre; 3Division of Pathology, University Hospital for Tumors, "Sestre milosrdnice" University Hospital Centre
| |
Collapse
|
21
|
Yu ST, Sun BH, Ge JN, Shi JL, Zhu MS, Wei ZG, Li TT, Zhang ZC, Chen WS, Lei ST. CRLF1-MYH9 Interaction Regulates Proliferation and Metastasis of Papillary Thyroid Carcinoma Through the ERK/ETV4 Axis. Front Endocrinol (Lausanne) 2020; 11:535. [PMID: 32982961 PMCID: PMC7477767 DOI: 10.3389/fendo.2020.00535] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Accepted: 06/30/2020] [Indexed: 12/13/2022] Open
Abstract
In our previous study, we have shown that CRLF1 can promote proliferation and metastasis of papillary thyroid carcinoma (PTC); however, the mechanism is unclear. Herein, we investigated whether the interaction of CRLF1 and MYH9 regulates proliferation and metastasis of PTC cells via the ERK/ETV4 axis. Immunohistochemistry (IHC), qPCR, and Western blotting assays were performed on PTC cells and normal thyroid cells to profile specific target genes. In vitro assays and in vivo assays were also conducted to examine the molecular mechanism. Results showed that CRLF1 directly bound MYH9 to enhance the stability of CRLF1 protein. Inhibition of MYH9 in PTC cells overexpressing CRLF1 significantly reversed malignant phenotypes, and CRLF1 overexpression activated ERK pathway, in vitro, and in vivo. RNA-sequencing revealed that ETV4 is a downstream target gene of CRLF1, which was up-regulated following ERK activation. Moreover, it was revealed that ETV4 is highly expressed in PTC tissues and is associated with poor prognosis. Finally, the ChIP assays showed that ETV4 induces the expression of matrix metalloproteinase 1 (MMP1) by binding to its promoter on PTC cells. Altogether, our study demonstrates that CRLF1 interacts with MYH9, promoting cell proliferation and metastasis via the ERK/ETV4 axis in PTC.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Animals
- Apoptosis
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Cell Proliferation
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- MAP Kinase Signaling System
- Male
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Middle Aged
- Myosin Heavy Chains/genetics
- Myosin Heavy Chains/metabolism
- Prognosis
- Protein Interaction Domains and Motifs
- Proto-Oncogene Proteins c-ets/genetics
- Proto-Oncogene Proteins c-ets/metabolism
- Receptors, Cytokine/genetics
- Receptors, Cytokine/metabolism
- Survival Rate
- Thyroid Cancer, Papillary/genetics
- Thyroid Cancer, Papillary/metabolism
- Thyroid Cancer, Papillary/secondary
- Thyroid Neoplasms/genetics
- Thyroid Neoplasms/metabolism
- Thyroid Neoplasms/pathology
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
- Young Adult
Collapse
|